AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04585152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Biosimilar
Description: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
Study NCT04585152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
Study NCT02669069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS1
Description: Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are synchronous with the tones.
Study NCT02669069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS2
Description: Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
Study NCT02669069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS3
Description: Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT03352050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ground beef
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT04170023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral FD inhibitor
Study NCT01205282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Study NCT01802645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Study NCT01205282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be a 2 week period of placebo run-in.
Study NCT04440969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Description: Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app.
Study NCT03574909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
Study NCT03574909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
Study NCT02724761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemic Epinephrine
Description: 1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
Study NCT02724761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for racemic epinephrine)
Description: 0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
Study NCT00972712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Tipifarnib
Description: Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)
Study NCT02721758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Study NCT03972423 — intervention group
Intervention type: OTHER
Intervention: With or wiyhout a checklist
Description: The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
Study NCT01287338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine
Description: low dose
Study NCT01287338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine
Description: high dose
Study NCT03544775 — intervention group
Intervention type: PROCEDURE
Intervention: Isolated General Anesthesia
Description: No nerve block identified through physician billing codes
Study NCT03544775 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral Nerve Block
Description: Nerve block identified through physician billing codes
Study NCT02205970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
Study NCT02205970 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS (sham)
Description: In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
Study NCT03818880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Spectacle lens to control progression of myopia
Study NCT04166149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: dd-cfDNA Blood Test
Description: The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
Study NCT03017586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beijing Pins Medical Co., Ltd. Deep Brain Stimulator
Description: Deep Brain Stimulation for primary dystonia subjects
Study NCT02651714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Study NCT02651714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01976078 — intervention group
Intervention type: DRUG
Intervention: Midazolam/Ranitidine/Esomeprazole
Description: Each of the three drugs will be given at 10% of their usual doses for age/weight.
Study NCT02779465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
Study NCT01850264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of quadripolar / bipolar LV electrodes
Study NCT02910583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: ibrutinib administered orally once daily (three 140 mg capsules)
Study NCT03242980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured adherence counseling
Description: Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling.
Study NCT03859050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchoscopy with intrabronchial administration of lipopolysaccharide
Description: The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
Study NCT01902901 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing
Description: Participants will receive Whole Genome Sequencing
Study NCT01026649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheterization
Description: Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
Study NCT01026649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheterization
Description: Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
Study NCT00625339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 0.5 mg QD
Study NCT00625339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study NCT03493919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ vaccine
Description: Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.
Study NCT03493919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: One dose of MenACWY vaccine were administered intramuscularly at Day 1.
Study NCT01902901 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Carrier status testing
Description: Carrier status testing
Study NCT01902901 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Carrier status testing
Description: Carrier status testing
Study NCT02920944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNB with 20 gauge ProCore needle
Description: EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
Study NCT02920944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB with 22 gauge ProCore needle
Description: EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
Study NCT03485716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: running on a treadmill under normoxia or hypoxia
Description: * 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)
Study NCT03485716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: running on a treadmill under normoxia or hypoxia
Description: * 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)
Study NCT02310490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DA-13-007 right with left side Sculptra left side
Description: The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
Study NCT02310490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DA-13-007 left with left side Sculptra right side
Description: The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
Study NCT01235585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses, once a day for 52 weeks
Study NCT01235585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 1, once a day for 52 weeks
Study NCT01235585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 2, once a day for 52 weeks
Study NCT00660166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK-Cell Infusion
Description: The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
Study NCT01637558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 hourly LPV/r during TB treatment
Description: 8 hourly LPV/r during TB treatment
Study NCT01637558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT01637558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Study NCT03656900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS BA9/BA46
Description: 10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
Study NCT03656900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS BA46/BA9
Description: 10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
Study NCT03656900 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brain MRI
Description: T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
Study NCT03099590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: kudzu extract, puerarin
Description: Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
Study NCT03099590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matched sugar beet placebo capsules will serve as placebo.
Study NCT00493727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine(Mucomyst)
Study NCT05119049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise guideline
Description: The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
Study NCT05119049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise guideline
Description: The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
Study NCT03656900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical evaluation
Description: complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
Study NCT03358147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI 28.8 μg
Description: GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
Study NCT03358147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI 14.4 μg
Description: GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
Study NCT02910583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ibrutinib
Description: ibrutinib administered orally once daily (three 140 mg capsules)
Study NCT02910583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
Study NCT03656900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological assessment
Description: Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
Study NCT00409708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy
Study NCT00409708 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavior Therapy
Study NCT06396845 — intervention group
Intervention type: PROCEDURE
Intervention: robotic surgery
Description: robotic surgery
Study NCT06396845 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: laparoscopic surgery
Study NCT03016897 — intervention group
Intervention type: OTHER
Intervention: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Description: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Study NCT05452629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness induction (MI)
Description: In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.
Study NCT05452629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation (RI)
Description: In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.